JNJ-3792165

JNJ-3792165 is a pharmacological compound currently under investigation for its potential therapeutic applications. It is a selective and potent phosphodiesterase 4B (PDE4B) inhibitor.

Pharmacology[edit | edit source]

JNJ-3792165 is a potent inhibitor of the enzyme phosphodiesterase 4B. This enzyme is involved in the breakdown of cyclic adenosine monophosphate (cAMP), a molecule that plays a crucial role in various cellular processes. By inhibiting PDE4B, JNJ-3792165 increases the levels of cAMP in cells, which can have various effects depending on the cell type and the specific cellular processes involved.

Potential Therapeutic Applications[edit | edit source]

The potential therapeutic applications of JNJ-3792165 are currently being investigated. Due to its mechanism of action, it is thought that this compound could have potential applications in the treatment of various conditions where the regulation of cAMP levels could be beneficial. These could include inflammatory diseases, neurodegenerative diseases, and certain types of cancer.

Clinical Trials[edit | edit source]

As of now, JNJ-3792165 is in the early stages of clinical development. The safety, tolerability, and efficacy of this compound are being evaluated in clinical trials. The results of these trials will determine whether JNJ-3792165 has the potential to be developed into a new therapeutic drug.

References[edit | edit source]

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.